个体化治疗分子检测

个体化治疗——疗效最大化，毒性最小化

In the subgroup of 261 patients who were positive for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin–paclitaxel (HR = 0.48; 95% CI, 0.36-0.64; P <0.001), whereas in the subgroup of 176 patients who were negative for the mutation, progression-free survival was significantly longer among those who received carboplatin–paclitaxel (HR for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P <0.001).
一项覆盖了9个国家和地区，1217例病人的泛亚洲科研显示：没有相关的靶标却接受了靶向治疗，死亡风险将增加185%。

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57.

—— 新英格兰医学杂志. 2009; 361(10):947-57.

“Scientifically, we have never been in a better position to advance cancer treatment …we know how to personalize therapy to the unique genetics of the tumor, and the patient.”

“从科学角度上，我们正处于一种前所未有的有利位置来推动癌症治疗……我们知道如何根据患者和肿瘤独特的遗传特征将治疗方式个体化。”

Rickard L. Schilsky, M.D., President, ASCO, 2008
—— 2008年美国临床肿瘤协会（ASCO）大会主席 Richard L Schilsky.